Prolight is pleased to announce the filing of a sixth patent application relating to the Psyros™ high-sensitivity IVD platform. The Psyros™ system enables cost-effective high-sensitivity testing at the point-of-care through its single-molecule-counting technology. This new patent application enhances Prolight’s existing IP portfolio.
The latest patent application builds upon the existing portfolio and allows any type of fluorophore to work in the Psyros™ system, including organic, inorganic and quantum dot fluorophores. A key benefit is that more stable fluorophores can be used, making the systemeven more robust and manufacturable.
“The filing of this new patent application represents a strategic move to continue advancing our cutting-edge technology and safeguard our competitive edge” said Steve Ross, CTO at Prolight.
Prolight currently has five patent applications relating to the Psyros™ technology. Three of these have entered the national / regional phases and are being prosecuted in a range of territories, including Europe, USA, Canada, China, Japan and others. The remaining two are in the international PCT (Patent Cooperation Treaty) stage and will enter national / regional phases in 2025.
